A detailed history of Affinity Asset Advisors, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 35,000 shares of BGNE stock, worth $6.22 Million. This represents 1.36% of its overall portfolio holdings.

Number of Shares
35,000
Previous 110,000 68.18%
Holding current value
$6.22 Million
Previous $15.7 Million 49.93%
% of portfolio
1.36%
Previous 2.14%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$143.93 - $224.51 $10.8 Million - $16.8 Million
-75,000 Reduced 68.18%
35,000 $7.86 Million
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $3.61 Million - $4.86 Million
27,857 Added 33.91%
110,000 $15.7 Million
Q1 2024

May 14, 2024

BUY
$141.8 - $181.47 $11.6 Million - $14.9 Million
82,143 New
82,143 $12.8 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.